Last reviewed · How we verify
Diquafosol 3% ophthalmic solution
Diquafosol 3% ophthalmic solution, marketed by Samsung Medical Center, is a therapeutic agent with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging its unique mechanism of action to address unmet needs in its primary indication. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Diquafosol 3% ophthalmic solution |
|---|---|
| Sponsor | Samsung Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery (PHASE4)
- Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery (PHASE4)
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis (PHASE3)
- Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery
- Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIK (NA)
- Diquafosol vs Hyaluronic Acid for Diabetic Dry Eye (NA)
- Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients (PHASE3)
- Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRK (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |